Coegin Pharma har en solid IP-portfölj med 19 patentfamiljer inkluderande substanspatent, användarpatent, kombinationspatent och formuleringspatent. Patentfamiljerna i tabellen nedan har lämnats in i USA, Europa, Kanada, Japan, Australien och även i andra områden som Kina, Hongkong, Korea, Indien, Israel, Nya Zeeland och Norge.
1 FOL-005 Hair growth stimulation PCT/GB2012/051955
2 Peptides for treatment of diabetes PCT/EP2018/061547
3 Peptides fragments for treatment of diabetes PCT/EP2019/080563
4 Topical formulation of FOL-005 PCT/EP2020/061453
5 Peptides for use in skin and hair pigmentation PCT/EP2021/080032
6 FOL peptides for wound healing Priority application
7 FOL peptides for vascularization Priority application
03 AVX001/AVX002 type compounds for the treatment of glomerulonephritis PCT/EP2010/003384
04 Oxothiazole compounds and their use for the treatment of certain chronic inflammatory conditions PCT/EP2010/064687
06 Oxothiazole compounds and their use in the treatment of chronic inflammatory disorders and proliferative disorders such as cancer PCT/EP2014/051655
10 AVX001 type ketones for the treatment of skin cancer PCT/EP2015/061534
12a AVX001 and AVX002 in combination with BEZ235 PCT/EP2017/056022
12f AVX235 and AVX420 in combination with BEZ235 PCT/EP2017/056016
16a Formulation comprising AVX001 type ketones and silicone PCT/EP2017/073951
19b AVX420 type compounds in combination with PI3K inhibitors PCT/EP2020/063717
21 AVX001 type ketones for the treatment of fibrotic diseases PCT/EP2018/066028
23 Oxothiazole compounds for the treatment of fibrotic diseases PCT/EP2019/060544
25 AVX001/AVX002 type compounds for use in the prevention of metastasis in cancer PCT/EP2020/071168
26 AVX001/AVX002 type compounds for use in the treatment of actinic keratosis or squamous cell carcinoma PCT/EP2021/087848
27 2-Oxothiazole compositions for treatment for T-cell acute lymphoblastic leukemia Priority application